These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24360931)

  • 1. Challenges for new haemophilia products from a manufacturer's perspective.
    Schulte S
    Thromb Res; 2014 Nov; 134 Suppl 1():S72-6. PubMed ID: 24360931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
    Metzner HJ; Pipe SW; Weimer T; Schulte S
    Thromb Haemost; 2013 Nov; 110(5):931-9. PubMed ID: 24178510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioneering designs for recombinant coagulation factors.
    Schulte S
    Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S
    Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journey.
    Négrier C
    Thromb Res; 2016 May; 141 Suppl 3():S9-S12. PubMed ID: 27288065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2016 May; 141 Suppl 3():S5-8. PubMed ID: 27288064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion
    Lyseng-Williamson KA
    Drugs; 2017 Jan; 77(1):97-106. PubMed ID: 27988873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
    Mancuso ME; Mahlangu JN; Pipe SW
    Lancet; 2021 Feb; 397(10274):630-640. PubMed ID: 33460559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
    Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended half-life clotting factor concentrates: results from published clinical trials.
    Young G; Mahlangu JN
    Haemophilia; 2016 Jul; 22 Suppl 5():25-30. PubMed ID: 27405672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
    Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
    Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of haemophilia patients in East Germany prior to and after reunification in 1990.
    Lenk H
    Thromb Res; 2014 Nov; 134 Suppl 1():S57-60. PubMed ID: 24745720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate® P) in patients with haemophilia A.
    Klamroth R; Gottstein S; Orlovic M; Heinrichs C
    Thromb Res; 2014 Nov; 134 Suppl 1():S38-42. PubMed ID: 24256767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Back to the future: a recent history of haemophilia treatment.
    Mannucci PM
    Haemophilia; 2008 Jul; 14 Suppl 3():10-8. PubMed ID: 18510516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.